SEATTLE — In this Healio Video Perspective from the ASRS annual meeting, Dennis Marcus, MD, provides an update on the phase 3 Pagoda and Pavilion trials evaluating the Port Delivery System.
According to Marcus, the phase 3 Pagoda and Pavilion trials, which investigated the Port Delivery System with ranibizumab (Genentech), now called Susvimo, for the treatment of diabetic macular edema and diabetic retinopathy, respectively, met their primary endpoints and demonstrated positive safety results.
“We believe that with the increased surgical training, experience and techniques, and with